Related references
Note: Only part of the references are listed.Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Brian G. M. Durie et al.
LANCET (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Luciano J. Costa et al.
BLOOD ADVANCES (2017)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
S. K. Kumar et al.
LEUKEMIA (2010)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)